What happens when you take cbd with warfarin?
Warfarin is a narrow-therapeutic-index blood thinner, meaning small changes in its blood level can swing you from under-protected (clot risk) to over-anticoagulated (bleeding risk). The more potent S-enantiomer of warfarin is cleared primarily by the liver enzyme CYP2C9, with the R-enantiomer cleared mainly by CYP1A2 and CYP3A4. Cannabidiol (CBD) is a recognized inhibitor of CYP2C9 and CYP3A4 at clinically relevant exposures, and in laboratory studies CBD inhibits CYP2C9 with IC50 values in the low micromolar range that overlap with concentrations seen after standard oral CBD doses.
The practical consequence is that when you add CBD to a stable warfarin regimen, your liver clears warfarin more slowly, plasma warfarin rises, and your INR drifts upward. A frequently cited case report from the University of Alabama at Birmingham described a patient with epilepsy on stable warfarin whose INR climbed repeatedly after each up-titration of liquid cannabidiol; the team ultimately had to cut warfarin by approximately 30% to maintain a therapeutic INR. Other case series have described INR jumps from baseline values of 2-3 up to 4-9 with concurrent cannabinoid use, and several patients presented with active bleeding.
Why is this important?
An elevated INR is not just a number on a lab report. Bleeding from over-anticoagulation can be subtle (excessive bruising, gum bleeding, prolonged bleeding from minor cuts) or catastrophic (gastrointestinal hemorrhage, intracranial bleeding). Older adults, people with hypertension, recent surgery, falls, gastritis, or kidney disease are especially vulnerable. Because CBD is widely available over-the-counter as oils, gummies, tinctures, vape liquids, and topicals, many people start it without telling their anticoagulation clinic, and routine INR checks may be weeks apart - long enough for a dangerous bleed to occur.
The interaction is also dose-dependent and product-dependent. Pharmaceutical CBD (Epidiolex) is dosed in the hundreds of milligrams per day and produces the strongest CYP inhibition, but even consumer CBD products at 25-50 mg per day have caused measurable INR shifts in case reports. Full-spectrum products that also contain delta-9-THC add further CYP2C9 inhibition. Bioavailability varies wildly between products and routes (oral, sublingual, inhaled), so two people taking 'the same dose' on the label may reach very different blood levels.
What should you do?
If you are on warfarin and considering CBD, the safest action is to talk to the prescriber or anticoagulation clinic before the first dose, not after. There is no validated dose of CBD that is known to be safe with warfarin, so the management strategy is monitoring rather than avoidance for many patients.
- Tell your anticoagulation clinic before starting, stopping, or changing the dose of any CBD product, including topicals if used over large surface areas.
- Get an INR check within 3-5 days of starting or changing CBD, then weekly until two consecutive readings are in range.
- Keep the product and dose constant while on warfarin - switching brands, switching from oil to gummies, or changing dose all reset the clock and require re-monitoring.
- Watch for bleeding signs: easy bruising, nosebleeds longer than 10 minutes, pink or red urine, black tarry stools, coughing up blood, unusual headache, or vision changes - call the clinic immediately or go to the emergency department.
- Avoid combining CBD with other CYP2C9-affecting agents like fluconazole, amiodarone, and high-dose fish oil without specific guidance.
If your INR is consistently elevated after starting CBD, options include reducing the warfarin dose under clinic guidance, reducing or stopping the CBD product, or switching warfarin to a direct oral anticoagulant - but DOACs have their own CBD interaction concerns and need a prescriber decision.
Which specific products are affected?
The interaction is a class effect of cannabidiol, regardless of source. Pharmaceutical Epidiolex (cannabidiol oral solution, 100 mg/mL) at typical anti-seizure doses of 10-20 mg/kg/day produces the largest CYP2C9 inhibition and the most documented INR increases. Consumer products including CBD oil tinctures, softgels, capsules, gummies, vape cartridges, drinks, and sublingual sprays all contribute to systemic CBD exposure and should be treated as interacting. Full-spectrum hemp products that contain delta-9-THC or delta-8-THC add additional CYP2C9 inhibition. Topical CBD applied to small areas for joint pain has negligible systemic absorption and is generally lower risk, but transdermal patches and balms applied over large skin surfaces can produce measurable blood levels. Warfarin sold as Coumadin or Jantoven is affected identically.
The bottom line
CBD raises warfarin levels and INR through CYP2C9 inhibition, and the size of the shift is unpredictable from person to person and product to product. The published case literature shows shifts large enough to require 30% warfarin dose reductions and to cause clinical bleeding. If you take warfarin, treat any CBD product - prescription or over-the-counter - as a medication change: tell your anticoagulation clinic before you start, get an early INR check, keep the product constant, and seek urgent care for any bleeding signs.